Template:Hormone levels with oral estradiol
Appearance
-
Estradiol levels after a single oral dose of 2, 4, or 8 mg estradiol in premenopausal women.[1]
-
Estradiol and estrone levels following a single 2 mg dose of oral estradiol in postmenopausal women.[2]
-
Mean estradiol levels during 1 to 8 mg/day oral estradiol therapy alone or in combination with 100 to 200 mg/day spironolactone in transgender women.[3]
-
Levels of estradiol, estrone, and estrone sulfate following a single 2 mg oral dose of estradiol valerate in postmenopausal women.[6][7][8]
-
Estradiol levels after a single dose of 2 mg oral estradiol or 2 mg oral estradiol valerate and with continuous administration of 2 mg/day oral estradiol or 2 mg/day oral estradiol valerate (at steady state) in postmenopausal women.[9]
Template documentation
See also
References
- ^ Kuhnz W, Gansau C, Mahler M (September 1993). "Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol". Arzneimittelforschung. 43 (9): 966–73. ISSN 0004-4172. PMID 8240460.
- ^ Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (December 2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.
- ^ Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgend Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC 5944393. PMID 29756046.
- ^ Yen SS, Martin PL, Burnier AM, Czekala NM, Greaney MO, Callantine MR (March 1975). "Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17beta-estradiol in postmenopausal women". J. Clin. Endocrinol. Metab. 40 (3): 518–21. doi:10.1210/jcem-40-3-518. PMID 1117058.
- ^ Quirk, J. Gerald; Wendel, George D. (1983). "Biologic Effects of Natural and Synthetic Estrogens". In J.J. Buchsbaum (ed.). The Menopause. pp. 55–75. doi:10.1007/978-1-4612-5525-3_5. ISBN 978-1-4612-5525-3. ISSN 0178-0328.
- ^ Aedo AR, Landgren BM, Diczfalusy E (November 1990). "Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women". Maturitas. 12 (4): 333–43. doi:10.1016/0378-5122(90)90013-v. PMID 2124648.
- ^ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
- ^ Kuhl, H. (1998). "Pharmakologie von Sexualsteroiden". Der Gynäkologe. 31 (10): 832. doi:10.1007/s001290050341. ISSN 0017-5994. S2CID 20941492.
- ^ Wiegratz I, Fink T, Rohr UD, Lang E, Leukel P, Kuhl H (September 2001). "Überkreuz-Vergleich der Pharmakokinetik von Estradiol unter der Hormonsubstitution mit Estradiolvalerat oder mikronisiertem Estradiol" [Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol]. Zentralbl Gynakol (in German). 123 (9): 505–12. doi:10.1055/s-2001-18223. PMID 11709743.